Glimepiride

• Description :

  Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.

• Product Name Alternative :

  Glimperide; HOE-490

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H319, H331, H361

• Target :

  Amyloid-β

• Type :

  Reference compound

• Related Pathways :

  Neuronal Signaling

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/glimepiride.html

• Concentration :

  10mM

• Purity :

  99.92

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

• Smiles :

  O=C(N1C(C(CC)=C(C)C1)=O)NCCC2=CC=C(S(=O)(NC(N[C@H]3CC[C@H](C)CC3)=O)=O)C=C2

• Molecular Formula :

  C24H34N4O5S

• Molecular Weight :

  490.62

• Precautions :

  H301, H319, H331, H361

• References & Citations :

  [1]Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38 (8) : p. 1120-30.|[2]Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4.|[3]Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS) . [corrected]. Vasc Health Risk Manag, 2012. 8: p. 463-72.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [93479-97-1]